Veltek Associates, Inc.

In this Drug Digest video, our speakers will discuss CDMOs and their ever-changing role in the biopharma space and current barriers in cell and gene therapy (CGT) manufacturing. Join the Drug Digest video to help prepare for manufacturing and cell/gene therapy challenges. Learn how digitalization, CDMOs, and CGT relate to conventional biopharma development and manufacturing.

https://www.pharmtech.com/pt_w/accelerating-biopharma

The biopharmaceutical industry has seen a lot of change in recent years, between new collaborations with supplier and contract development and manufacturing organizations (CDMOs) and accelerated drug delivery times. According to recent research, biopharmaceutical figures are already using digital and analytics for their benefit, with an increase of up to 40% in plant capacity, 20% in lead time, and 15% reduction in conversion costs (1).


With more growth comes more responsibilities, and processes like cell and gene therapy are on the forefront for the latest strategies to overcome the challenges in the manufacturing space.
In this Drug Digest video, Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services at Thermo Fisher Scientific, and Jason C. Foster, CEO and executive director at Ori Biotech, will provide expert insights into what happens in the manufacturing space from a CDMO and a cell/gene therapy perspective.

Reimagining the future of biopharma manufacturing

. October 11, 2022. https://www.mckinsey.com/industries/life-sciences/our-insights/reimagining-the-future-of-biopharma-manufacturing

The ability to identify the benefits of biopharma companies partnering with a CDMO

The ability to learn about different kinds of cell and gene therapies and how to overcome the barriers in the continuous manufacturing space

Problem solving: ability to develop a plan for concepts, such as scalability and being more cost efficient, with new products and techniques

Awareness: ability to successfully pinpoint new approaches to medicine and how to respond as a biopharma company


Global Head of Technical and Scientific Affairs
Pharma Services at Thermo Fisher Scientific

Webcasts

Webinar Date/Time: Thu, Jul 20, 2023 11:00 AM EDT


Accelerating Biopharma Development and Manufacturing through CDMOs and CGT

	Veltek Associates, Inc. has developed an innovative, patent pending, product that nearly eliminates the problematic issue of correct aseptic cart transference. Current industry practice for cleaning and disinfection of the upper portions of the cart, while labor intensive, are manageable. However, cleaning of bases, wheels, casters, and underneath the cart are virtually impossible, can cause numerous problems, and complicate worker safety.

	The Cart2Core™, Aseptic Cart Transferring System, provides the ability for cleanroom operations to transfer materials through classified areas while reducing the possibility of cross-contamination. A previously arduous process has become simple. The cart top is able to be transferred to another previously cleaned cart base located in the next classified area. Simply lift the handle and slide the top of the cart onto the next base, leaving the potential contamination behind.

	Available cart configurations include: a Micro Cart for production, micro, and cleaning personnel, a Can and Bottle Cart designed to convey large cans and bottles, a Tray Cart for transporting trays of vials, parts, and other needed items, and a Utility Cart for everyday use that is also ideal for pass throughs. All carts are autoclavable, sterilizable, chemical resistant, have the capability to be RFID coded, and are constructed of 316L Stainless Steel.

	Company name: Veltek Associates, Inc.
	Website: 

Articles

VAI’s Cart2Core®, a patent pending technology, virtually eliminates the problematic issue of correct aseptic cart transference by making the cart top transferable to a new base at each new classification. 